Reece, K. M., Richardson, E. D., Cook, K. M., Campbell, T. J., Pisle, S. T., Holly, A. J., . . . Figg, W. D. (2014). Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. BioMed Central.
Chicago-tyylinen lähdeviittausReece, Kelie M., et al. Epidithiodiketopiperazines (ETPs) Exhibit in Vitro Antiangiogenic and in Vivo Antitumor Activity By Disrupting the HIF-1α/p300 Complex in a Preclinical Model of Prostate Cancer. BioMed Central, 2014.
MLA-viiteReece, Kelie M., et al. Epidithiodiketopiperazines (ETPs) Exhibit in Vitro Antiangiogenic and in Vivo Antitumor Activity By Disrupting the HIF-1α/p300 Complex in a Preclinical Model of Prostate Cancer. BioMed Central, 2014.